CN Mobile Logo


Hematologic Malignancies

Hematologic Malignancies

A new study found that monitoring of minimal residual disease in a group of elderly patients with multiple myeloma proved to have important prognostic value, regardless of patient age or cytogenetic risk.

The advantage of treating low- or intermediate-risk APL with ATRA plus arsenic trioxide appears to increase over time, according to results of the APL0406 trial.

Results of a single-center analysis indicated that patients aged 80 or older with DLBCL had superior outcomes with anthracycline-based therapies.

Combination treatment with obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly delayed disease progression in patients with indolent non-Hodgkin lymphoma refractory to rituximab.

Continuous lenalidomide plus low-dose dexamethasone reduced the risk for progression in untreated multiple myeloma patients who were ineligible for stem cell transplantation.

Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.

Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.